Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 22
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Dose-Finding and Double Blinded Study of JNS020 QD(Fentanyl) in Patients With Cancerous Pain Previously Untreated With Opioid Analgesics
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care
Closed
20 and over
Pharmaceutical / Industry
CR014899
JNS020QD-JPN-C02, FENPAI2003, NCT00644787
Last Modified:
12/1/1991
2.
Phase III Study of Transdermally Delivered Fentanyl vs Placebo for Pain Management in Cancer Patients (Summary Last Modified 12/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
18 and older
NCI
NCCTG-889252
MAYO-889252, NCI-P91-0015
3.
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 to 80
Pharmaceutical / Industry
C25608/3039/BP/US
NCT00105287
4.
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 to 80
Pharmaceutical / Industry
099-15
NCT00105937
5.
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 to 75
Pharmaceutical / Industry
ZMF-301
NCT00126789
6.
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
18 and over
Pharmaceutical / Industry
FEN-202
NCT00293020
7.
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 and over
Pharmaceutical / Industry
FEN-201
NCT00293033
8.
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 to 80
Pharmaceutical / Industry
FT-018-IM
2005-002348-24, NCT00362583
9.
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
18 and over
Pharmaceutical / Industry
FT-019-IM
2006-002087-26, NCT00496392
10.
An Effectiveness and Safety Study of Fentanyl in Patients With Cancer Pain Changing From Opioid Analgesics
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
20 and over
Pharmaceutical / Industry
CR014896
NCT00641667
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute